Clinical Research Directory

Inclusion Criteria: * Any sex or gender; any race or ethnicity; aged 18 years or older * Patient participants must meet DSM-5 diagnostic criteria for current (i.e., past 12 months) OUD (assessed via the Quick Structured Clinical Interview for DSM-5; Quick SCID) * Patient participants must be on buprenorphine, as prescribed by their provider, for no more than 4 weeks prior to study initiation * Patient participants must be in treatment at one of the following clinics in the Charleston area: MUSC's Center for Drug and Alcohol Programs (CDAP) clinic, MUSC's Bridge Clinic, the Charleston Center, Hope Integrative Medicine, or BHG Charleston * Concurrent substance use disorders (e.g., alcohol, cannabis) for the patient participant are acceptable, provided opioids are the patient participant's primary substance of choice * Patient participants must identify a CSO participant who consents to participation in the study as well Exclusion Criteria: * Moderate-to-severe opioid withdrawal as defined by a score of ≥21 on the Subjective Opioid Withdrawal Scale * Meeting DSM-5 criteria for a history of or current psychotic or bipolar disorders * Current suicidal or homicidal ideation and intent; participants who present a serious suicide risk are likely to require hospitalization during the study and they will be referred clinically * CSO participants meeting DSM-5 criteria for opioid use disorder or any other substance use disorder, excepting tobacco use disorder * Severe interpersonal violence in the past six months between the patient and the CSO, as defined by an adapted version of the Conflict Tactics Scaled Revised (CTS-2) * Pregnancy for patient participants * Prisoners, institutional individuals, and children will not be recruited for this study.